Luspatercept
Showing 26 - 38 of 38
Erythrocyte Transfusion, Beta-Thalassemia Trial in Worldwide (Luspatercept, Placebo)
Completed
- Erythrocyte Transfusion
- Beta-Thalassemia
- Luspatercept
- Placebo
-
Los Angeles, California
- +72 more
Jan 21, 2022
MDS Trial in Worldwide (Luspatercept, Placebo)
Completed
- Myelodysplastic Syndromes
- Luspatercept
- Placebo
-
Stanford, California
- +73 more
Nov 19, 2021
MDS (MDS), Beta-thalassemia, Myeloproliferative Tumor(MPN)-Associated Myelofibrosis Trial in Worldwide (Luspatercept)
Recruiting
- Myelodysplastic Syndromes (MDS)
- +2 more
- Luspatercept
-
Los Angeles, California
- +203 more
Jan 30, 2023
Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis Trial in Worldwide (ACE-536, Placebo)
Recruiting
- Myeloproliferative Disorders
- +4 more
- ACE-536
- Placebo
-
La Jolla, California
- +184 more
Aug 22, 2022
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)
Recruiting
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
-
Ocala, Florida
- +3 more
Jan 30, 2023
Minimisation Measures for REBLOZYL Among Healthcare
Active, not recruiting
- Myelodysplastic Syndromes
- Beta-thalassemia
-
City, State, AustriaLocal Institution
Aug 4, 2022
Transfusion-dependent Beta-Thalassemia Trial in Peshawar (Thalidomide)
Completed
- Transfusion-dependent Beta-Thalassemia
-
Peshawar, Khyber Pakhtunkhwa, PakistanBlood Care Clinic
Nov 19, 2023
Low Risk MDS Trial (R906289 Monosodium (R289 Na))
Not yet recruiting
- Low Risk Myelodysplastic Syndromes
- R906289 Monosodium (R289 Na)
- (no location specified)
Jul 22, 2022
Myeloproliferative Tumor Trial in New York (Vactosertib)
Recruiting
- Myeloproliferative Neoplasm
-
New York, New YorkWeill Medical College of Cornell University
Dec 20, 2021
GENOMED4ALL: Improving MDS Classification and Prognosis by AI
Active, not recruiting
- Myelodysplastic Syndromes
-
Milano, ItalyIstituto Clinico Humanitas
Jun 28, 2021
l Research in Myelodysplastic Syndromes
Recruiting
- Myelodysplastic Syndromes
-
Paris, France
- +3 more
Nov 20, 2019
Anemia Trial in Tempe (ACE-536, Placebo)
Completed
- Anemia
- ACE-536
- Placebo
-
Tempe, ArizonaAcceleron Investigative Site
Nov 5, 2012